Radhakrishnan Archana, Grande David, Mitra Nandita, Pollack Craig Evan
Division of General Medicine, University of Michigan, Ann Arbor, MI.
Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA.
Urology. 2018 May;115:133-138. doi: 10.1016/j.urology.2018.01.048. Epub 2018 Mar 28.
To examine how frequently patients report that their urologist recommended forgoing definitive treatment and assess the impact of these recommendations on treatment choice and perceived quality of cancer care.
We mailed surveys to men newly diagnosed with localized prostate cancer between 2014 and 2015 (adjusted response rate of 51.3%). Men reported whether their urologist recommended forgoing definitive treatment. Using logistic regression models, we assessed patient-level predictors of receiving a recommendation to forgo definitive treatment and estimated associations of receiving this recommendation with receipt of definitive treatment and perceived quality of cancer care among men with low-risk tumors and limited life expectancies.
Nearly two-thirds (62.2%) of men with low-risk tumors and 46.4% with limited life expectancies received recommendations from their urologists to forgo definitive treatment. Among men with limited life expectancies, those with low-risk tumors were more likely to receive this recommendation compared with men with high-risk tumors (odds ratio [OR] 3.41; 95% confidence interval [CI] 2.17-5.37). Men with low-risk tumors who were recommended to forgo definitive treatment were less likely to receive definitive treatment (OR 0.48; 95% CI 0.32-0.73) but did not report lower perceived quality of care (OR 0.97; 95% CI 0.63-1.48).
In this population-based study, a majority of men with low-risk prostate cancer report receiving recommendations from their urologists to forgo definitive treatment. Our results suggest that urologists have a strong influence on patient treatment choice and could increase active surveillance uptake in men eligible for expectant management without patients perceiving lower quality of cancer care.
研究患者报告其泌尿科医生建议放弃确定性治疗的频率,并评估这些建议对治疗选择和癌症护理感知质量的影响。
我们向2014年至2015年间新诊断为局限性前列腺癌的男性邮寄了调查问卷(调整后的回复率为51.3%)。男性报告他们的泌尿科医生是否建议放弃确定性治疗。使用逻辑回归模型,我们评估了接受放弃确定性治疗建议的患者层面预测因素,并估计了接受该建议与低风险肿瘤和预期寿命有限的男性接受确定性治疗以及癌症护理感知质量之间的关联。
近三分之二(62.2%)的低风险肿瘤男性和46.4%预期寿命有限的男性收到了泌尿科医生放弃确定性治疗的建议。在预期寿命有限的男性中,与高风险肿瘤男性相比,低风险肿瘤男性更有可能收到此建议(优势比[OR] 3.41;95%置信区间[CI] 2.17 - 5.37)。被建议放弃确定性治疗的低风险肿瘤男性接受确定性治疗的可能性较小(OR 0.48;95% CI 0.32 - 0.73),但未报告较低的护理感知质量(OR 0.97;95% CI 0.63 - 1.48)。
在这项基于人群的研究中,大多数低风险前列腺癌男性报告收到了泌尿科医生放弃确定性治疗的建议。我们的结果表明,泌尿科医生对患者的治疗选择有很大影响,并且可以增加符合观察等待管理条件的男性对主动监测的接受度,而患者不会感觉到癌症护理质量降低。